A causal link between autoantibodies and neurological symptoms in long COVID 2309692

K Keyla Sa (Yale University) J Julio Silva (Yale University) R Rafael Bayarri-Olmos (Yale School of Medicine) C Christopher A Baker (Yale University) Z Zhenni Lu (Yale University) W Wilson Gipson (Yale University) D Daxiang Na B Bandy Chen L Li Wenxue (Yale University) D Delyar Khosroabadi (Yale University) R Ryan Brinda (Yale University) R Robert Constable (Yale University) B Britney Omene (Yale University) P Patricia Colom Díaz (Yale University) D Dong-il Kwon (Yale School of Medicine) S Sachin Bhagchandani (Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital) B Bornali Bhattacharjee (Yale University) J Jeffrey Gehlhausen (Yale University) J Jamie Wood (Icahn School of Medicine at Mount Sinai) L Laura Tabacof (Icahn School of Medicine at Mount Sinai) Y Yansheng Liu L Leying Guan M Marc Pane (Yale University) D David Putrino T Tamas Horvath (Yale University) A Akiko Iwasaki (Department of Immunobiology, Yale School of Medicine)

Abstract

Abstract Introduction Acute SARS-CoV-2 infection triggers the de novo production of diverse and functional autoantibodies (AABs), even after mild illness. Previous studies have shown that autoantibodies remain persistently elevated in a subset of individuals with Long COVID (LC). However, it is still unclear whether these autoantibodies drive pathogenesis of LC Methods Using a human protein array with over 21,000 proteins and an antibody pull-down of autoantigens followed by mass spectrometry, we identified a broad range of AAB targets among individuals with LC that correlated with their symptom profiles. In order to evaluate if those autoantibodies were pathogenic, we developed a passive transfer mouse model by injecting total IgG in mice and performing a battery of behavior analysis. Results We found increased AABs against proteins in the central and peripheral nervous systems, as well as peripheral tissues, in individuals with LC displaying neurocognitive and neurological symptoms. Purified immunoglobulin G (IgG) samples from these individuals reacted with tissue sections of human locus coeruleus, thalamus, adrenal gland, thyroid, and showed cross-reactivity with mouse sciatic nerve and meninges. Autoantibody levels reactive to CNS antigens were linked to symptoms such as headaches and loss of taste and smell. Passive transfer of IgG from patients to naïve mice caused increased fatigue-like behavior and thermal hyperalgesia, aligning with patients’ reports of chronic pain. Similarly, loss of balance and coordination in the rotarod test in mice injected with IgG matched with patient-reported dizziness. Moreover, transfer of purified IgG from patients with chronic pain caused damage to small peripheral nerve fibers and increased neuronal activity in pain-related brain regions in mice. Conclusion Our findings demonstrate that transferring IgG from LC patients into mice can reproduce certain neurological symptoms, suggesting that targeting AABs might offer therapeutic benefits for this subgroup of LC. Funding Source Pew Latin American Fellowship Topic Categories Immune Mechanisms of Human Disease (HUM)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (26)

K

Keyla Sa

Yale University

J

Julio Silva

Yale University

R

Rafael Bayarri-Olmos

Yale School of Medicine

C

Christopher A Baker

Yale University

Z

Zhenni Lu

Yale University

W

Wilson Gipson

Yale University

D

Daxiang Na

B

Bandy Chen

L

Li Wenxue

Yale University

D

Delyar Khosroabadi

Yale University

R

Ryan Brinda

Yale University

R

Robert Constable

Yale University

B

Britney Omene

Yale University

P

Patricia Colom Díaz

Yale University

D

Dong-il Kwon

Yale School of Medicine

S

Sachin Bhagchandani

Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital

B

Bornali Bhattacharjee

Yale University

J

Jeffrey Gehlhausen

Yale University

J

Jamie Wood

Icahn School of Medicine at Mount Sinai

L

Laura Tabacof

Icahn School of Medicine at Mount Sinai

Y

Yansheng Liu

L

Leying Guan

M

Marc Pane

Yale University

D

David Putrino

T

Tamas Horvath

Yale University

A

Akiko Iwasaki

Department of Immunobiology, Yale School of Medicine